Photopheresis Devices Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Photopheresis Devices Market By Product Type (Open System, Closed System), By Disease Indication (Autoimmune diseases, Graft versus host disease, Cutaneous T-cell lymphoma, Transplant rejections), By Distribution Channel (Hospitals, Ambulatory Care, Others), and Geography.

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global Photopheresis Devices Market was valued at USD 267.78 million in 2020 and is anticipated to grow at USD 397.35 million by end of 2027 recording a CAGR of 5.9% during the forecast period 2021-2027. Photopheresis is a form of apheresis in which small amount of the blood is treated with photosensitizing agent. Photopheresis is popular for its therapeutic option used in various autoimmune diseases, organ transplantation such as kidney and liver advanced cutaneous T-cell lymphoma and acute and chronic graft versus host disease (GVHD). U.S. FDA in 1988, has first approved extracorporeal photopheresis (ECP) which is now known as extracorporeal photo immunotherapy, as leukapheresis-based therapeutic procedure. In Photopheresis, the white blood cells are collected after being exposed to the UVA radiation, 8-MOP. As far as devices of photopheresis are concerned, many open and closed systems available in the market, of which only closed systems are approved by the U.S. FDA due to its lesser risk of contamination, flaws and infection during reinfusion. Photopheresis is a type of photodynamic therapy in which blood is treated with a blood sensitising chemical that has been exposed to a specific wavelength of light. Photopheresis products are in high demand all around the world. The rising incidence of autoimmune illnesses, as well as the rising number of organ transplant cases, are driving the global photopheresis products market. Growing health-care infrastructure, advancements in advanced technology, and an ageing population are all drivers that will propel the market forward. In August 2016, Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced that Switzerland’s Federal Department of Home Affairs (FDHA) has approved reimbursement of Extracorporeal Photopheresis (ECP) treatment for patients in Switzerland with Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation. Mallinckrodt Pharmaceuticals provides ECP therapy through its THERAKOS therapeutic platforms, including the latest generation THERAKOS CELLEX Photopheresis System

 

 


Global Photopheresis Devices Market

MARKET SUMMARY
-
5.9%
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 5.9%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Photopheresis Devices Market

  • Photopheresis devices market is segmented based on the product type, disease indication, and distribution channel
  • Photopheresis Devices Market gives historical, current, and future market sizes (US$ Mn) of product type and distribution channel and geographic regions.
  • This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
  • In addition, the market report includes regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.
  • Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities).
  • Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of Infant nutrition
Market Key Players
  • Macopharma
  • Haemonetics Corporation
  • Fresenius Kabi AG
  • Terumo Corporation
  • Mallinckrodt Pharmaceuticals
Growth

Photopheresis Devices Market

The increasing prevalence of autoimmune diseases and rising number of organ transplant cases are expected to drive the photopheresis devices market. The safer and effective treatment promised by the introduction of these devices is one of the major factor expected to drives photopheresis devices market. The increased government reimbursement policies and private health insurance is playing a key role in the growth of the market. The awareness about ECP therapy will boost the market. However, the higher cost, time, constant therapy sessions are expected to hinder the market. The availability of lesser number of ECP therapy centers is expected to dampen the market.


North-America Got Significant Share

Photopheresis Devices Market

Geographically, global photopheresis devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America photopheresis devices market is dominant in thephotopheresis devices market. The huge reimbursements provided by the government for various treatments such as GVHD, CTL, and lung transplantations which is treated by ECP therapy is a key factor expected to drive the market. However, Asia Pacific is expected to dominate the market due to increased initiatives in terms of the expansion of the photopheresis products market over the forecast period. The increasing count of photopheresis centers is expected to drive the market. The faster regulatory approvals is expected fuel the market in future.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Photopheresis Devices Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Macopharma
  • Haemonetics Corporation
  • Fresenius Kabi AG
  • Terumo Corporation
  • Mallinckrodt Pharmaceuticals

Description

Global Photopheresis Devices Market was valued at USD 267.78 million in 2020 and is anticipated to grow at USD 397.35 million by end of 2027 recording a CAGR of 5.9% during the forecast period 2021-2027. Photopheresis is a form of apheresis in which small amount of the blood is treated with photosensitizing agent. Photopheresis is popular for its therapeutic option used in various autoimmune diseases, organ transplantation such as kidney and liver advanced cutaneous T-cell lymphoma and acute and chronic graft versus host disease (GVHD). U.S. FDA in 1988, has first approved extracorporeal photopheresis (ECP) which is now known as extracorporeal photo immunotherapy, as leukapheresis-based therapeutic procedure. In Photopheresis, the white blood cells are collected after being exposed to the UVA radiation, 8-MOP. As far as devices of photopheresis are concerned, many open and closed systems available in the market, of which only closed systems are approved by the U.S. FDA due to its lesser risk of contamination, flaws and infection during reinfusion. Photopheresis is a type of photodynamic therapy in which blood is treated with a blood sensitising chemical that has been exposed to a specific wavelength of light. Photopheresis products are in high demand all around the world. The rising incidence of autoimmune illnesses, as well as the rising number of organ transplant cases, are driving the global photopheresis products market. Growing health-care infrastructure, advancements in advanced technology, and an ageing population are all drivers that will propel the market forward. In August 2016, Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced that Switzerland’s Federal Department of Home Affairs (FDHA) has approved reimbursement of Extracorporeal Photopheresis (ECP) treatment for patients in Switzerland with Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation. Mallinckrodt Pharmaceuticals provides ECP therapy through its THERAKOS therapeutic platforms, including the latest generation THERAKOS CELLEX Photopheresis System

 

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX